• Citer

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

par Keymeulen, B;Walter, M;Mathieu, C;Kaufman, L.;Gorus, F;Hilbrands, Robert;Vandemeulebroucke, Evy;Van de Velde, U;Crenier, Laurent ;De Block, Christophe;Candon, Sophie;Waldmann, Herman;Ziegler, Anette Gabriele;Chatenoud, Lucienne;Pipeleers, D
Référence Diabetologia, 53, 4, page (614-623)
Publication Publié, 2010-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
Auteur:	Keymeulen, B; Walter, M; Mathieu, C; Kaufman, L.; Gorus, F; Hilbrands, Robert; Vandemeulebroucke, Evy; Van de Velde, U; Crenier, Laurent; De Block, Christophe; Candon, Sophie; Waldmann, Herman; Ziegler, Anette Gabriele; Chatenoud, Lucienne; Pipeleers, D
Informations sur la publication:	Diabetologia, 53, 4, page (614-623)
Statut de publication:	Publié, 2010-04
Sujet CREF:	Diabétologie
MeSH keywords:	Adult
	Age Factors
	Antibodies -- therapeutic use
	Antigens, CD3 -- immunology
	Belgium
	Diabetes Mellitus, Type 1 -- drug therapy -- immunology
	Female
	Follow-Up Studies
	Hemoglobin A, Glycosylated -- metabolism
	Humans
	Insulin-Secreting Cells -- physiology
	Lymphocyte Subsets -- immunology
	Male
	Placebos
	Registries
	Time Factors
	Young Adult
Note générale:	Clinical Trial, Phase II
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0012-186X
	info:doi/10.1007/s00125-009-1644-9
	info:scp/77949266510
	info:pmid/20225393